Ethel Weld, MD

Protocol chair, IMPAACT 2005
Protocol vice-chair, IMPAACT 2022
Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
Member, Pharmacology Core, HPTN Laboratory Core
Member, TB in Pregnancy Working Group
Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Johns Hopkins University Baltimore-India Clinical Trials Unit